Despite treatment with the current standard-of-care therapies, patients with newly diagnosed
glioblastoma multiforme (GBM) exhibit dismal prognoses. Bevacizumab has demonstrated …

Background Concurrent treatment with temozolomide and radiotherapy followed by
maintenance temozolomide is the standard of care for patients with newly diagnosed …

Background Standard therapy for newly diagnosed glioblastoma is radiotherapy plus
temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab …

Purpose This open-label, prospective, multicenter single-arm phase II study combined
bevacizumab (BV) with radiation therapy (RT) and temozolomide (TMZ) for the treatment of …

PURPOSE: To assess interim safety and tolerability of a 10-patient, Phase II pilot study using
bevacizumab (BV) in combination with temozolomide (TMZ) and regional radiation therapy …

1 Background: Chemoradiation (CRT) with temozolomide (TMZ/RT→ TMZ) is the standard of
care for newly diagnosed GBM. This trial determined if the addition of Bev to standard CRT …

Background The proposed use of bevacizumab with radiotherapy/temozolomide for newly
diagnosed glioblastoma raised potential safety concerns. Bevacizumab has been linked …

Purpose: To determine if the addition of bevacizumab to radiation therapy and
temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly …

High-grade glioma is a richly neovascularized brain solid tumor with a poor prognosis.
Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular …

• Glioblastomas are highly vascularized tumors characterized by overexpression of VEGF-
A1, 2• Bevacizumab (BEV) has shown activity in glioblastoma o Increased PFS and ORR vs …